PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
BUHLMANN Diagnostics Corp

Press Release

Share      Blog

Receive press releases from BUHLMANN Diagnostics Corp: By Email PDF Version RSS Feeds:

BUHLMANN Diagnostics Corp. Announces New Distribution Agreement with Meridian Biosciences, Inc.


BUHLMANN Diagnostics Corp. has embarked on a new partnership with Meridian Bioscience, Inc. for the distribution of the 510(k) cleared, BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool.

BUHLMANN Diagnostics Corp. Announces New Distribution Agreement with Meridian Biosciences, Inc.
Amherst, NH, January 31, 2019 --(PR.com)-- BUHLMANN Diagnostic Corp. (BDC), Amherst, NH is proud to announce they have entered into a distribution agreement with Meridian Bioscience, Inc., Cincinnati, Ohio to market the FDA-cleared BÜHLMANN fCAL® ELISA for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.

This partnership reflects BDC’s commitment to diagnostics and aim to expand reach to laboratories across the country. This collaboration also aligns with Meridian’s continuing efforts to deepen their GI product portfolio and extend their offerings to clinical laboratories, including Health System and Integrated Delivery Networks who look to standardize and optimize patient care.

BDC CEO, Doug Olson commented, “Today’s announcement is another great example of our efforts to support the gastroenterology field. Our partnership with Meridian is an important step in our collective goal of improving patient care by providing a quality fecal calprotectin assay with timely, accurate results to aid patient management.”

Visit www.buhlmannlabs.com to learn more about this assay, and overall performance.

About BÜHLMANN Laboratories AG
Founded in 1976, BÜHLMANN Laboratories AG has continued to focus on growing a product portfolio of in vitro diagnostics and research markets. BÜHLMANN is known for outstanding product quality, providing excellent after-sales services, and delivering remarkable scientific innovations. BÜHLMANN offers the broadest range of calprotectin products as well as a selection of unique, high-quality assays such as the BÜHLMANN Flow CAST® product group for Basophil Activation Testing, the BÜHLMANN GanglioCombi™ products for neuroimmunology, and a variety of Melatonin Assays.

About BUHLMANN Diagnostics Corp (BDC)
BUHLMANN Diagnostics Corp (BDC) is the North American affiliate of BÜHLMANN Laboratories AG, the worldwide provider of ELISA kits, RIA kits, lateral flow and flow cytometry assays. Located in Southern New Hampshire, BDC has a highly experienced team who represent a breadth of experience in serving both clinical and basic science research laboratories.

About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

About BÜHLMANN Calprotectin Product Line
The calprotectin portfolio consists of the BÜHLMANN fCAL® ELISA (FDA 510(k) cleared), BÜHLMANN fCAL® turbo for testing on most clinical chemistry analyzers (RUO in the US), Quantum Blue® fCAL Rapid Test (RUO in the US), and IBDoc®, the first and only Health Canada Licensed home-testing application for fecal calprotectin in IBD patients (IBDoc® not available for sale in the US).
Contact Information
BUHLMANN Diagnostics Corp
Stacy Smith
844-300-9799
Contact
www.buhlmannlabs.com
info@buhlmannlabs.com

Click here to view the list of recent Press Releases from BUHLMANN Diagnostics Corp
Promote Your Business